Pacira Pharmaceuticals (PCRX) Posts Q1 Loss of 19c/Share

Pacira Pharmaceuticals (NASDAQ: PCRX) reported Q1 EPS of ($0.19), $0.13 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $36.7 million versus the consensus estimate of $35.4 million.

For earnings history and earnings-related data on Pacira Pharmaceuticals (PCRX) click here.

You May Also Be Interested In

• JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
• EXL to acquire iMerit in deal valued at up to $310 million
• Ecolab pops as Citi sees improving setup into Q2 earnings